Sebastian Quincha Muñoz

CeleroSpace is taking on the challenge of new drug development where over 90% of candidates for new treatments don't make it to the market. We are combining advanced human models with microgravity to allow pharma companies and research centres to identify much earlier during the preclincial phases which compunds have greater potential to make it past the clinical trials. This will minimize the need of animal testing while complying with new regulations (FDA, NIH) which incentivate the use of NAMs to reduce animal testing during preclinical phases.